Therefore, antagonistic activity between PU.1 and other factors, such as GFI1, appear to be central to the consequences of LSD1 inhibition in AML, likely due to the interference of GFI1-mediated repression of PU.1 target genes (19, 28). The gene discussed is KDM1A; the disease is acute myeloid leukemia.